Goldfarb Branham LLP is investigating potential shareholder claims against the officers and directors of Johnson & Johnson due to lack of internal controls that led to phantom recalls and several class action lawsuits. Johnson & Johnson investors are encouraged to contact the firm at 877-583-2855 or hlindley@goldfarbbranham.com to learn about their rights.

“A class action complaint alleges that defendants received numerous complaints that Tylenol products made in Puerto Rico had a ‘musty’ odor, but failed to conduct an adequate investigation or notify the Federal Drug Administration,” securities lawyer Hamilton Lindley said. “It also alleges that company executives failed to take corrective actions when foreign materials were found in a Pennsylvania manufacturing facility. Additionally, when defendants learned of problems with its Motrin drug, they sent contractors to stores to purchase the product instead of mentioning a recall.”

Goldfarb Branham LLP is investigating a derivative lawsuit against company officers and directors for allowing this to occur. Derivative lawsuits often lead to restored confidence in companies involved in financial scandal and a resulting increase in shareholder value. Concerned shareholders who still hold their shares are urged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com.